Cancer of Head and Neck Clinical Trial
Official title:
Validation of High-resolution PET/CT for the Pretherapeutic Lymphnode Staging of Head/Neck Cancer
In head and neck squamous cell carcinoma (HNSCC), the presence of lymph node metastases in
addition to free resection margins following surgical resection of the primary tumor is an
important prognostic factor, and may impact planning of surgery as well as of radiotherapy.
Until now, imaging modalities including PET/CT and MRI did not allow to exclude especially
small lymph node metastases.
Compared to standard whole-body PET/CT acquisition techniques, high-resolution (HR) head and
neck PET/CT acquisitions promise improved detection of lymph node metastases in head and neck
squamous cell carcinoma (HNSCC). This prospective study aims to determine the sensitivity and
specificity of lymph node staging with HR FDG-PET/CT in HNSCC by correlating PET/CT with
histopathology after neck dissection. HR PET/CT may have a relevant impact on the therapeutic
concept, and the planning and dose prescription of radiotherapy.
In head and neck squamous cell carcinoma (HNSCC), the presence of lymph node metastases in
addition to free resection margins following surgical resection of the primary tumor is an
important prognostic factor, and may impact planning of surgery as well as of radiotherapy.
Neck dissection and histopathology are regarded as diagnostic standard procedures to define
the lymph node status in patients with HNSCC. Occult lymph node metastases after imaging have
been described in up to 46% of patients, e.g. in patients with cancer of the tongue.
Although neck dissection generally has a low rate of intra- and postoperative complications,
a small but statistically significant group of patients suffers from surgery-related side
effects such as lymphedema, chronic pain syndromes and injury of cranial nerves with
paralysis (shoulder lift and mouth angle). Therefore it would be desirable to spare
diagnostic neck dissection in patients without macroscopic lymph node metastasis. However,
the sensitivity and/or specificity of the non-invasive imaging techniques available up to
now, including positron emission tomography (PET) and magnetic resonance imaging (MRI), did
not allow to exclude lymph node metastases, which is especially true for small metastases.
Therefore, imaging is not able to replace the histological examination of the cervical lymph
nodes and have limited impact on the therapeutic concept, the surgical planning and the
planning and dose prescription of radiotherapy.
Acquisition techniques and image quality of PET (with the glucose analog
F-18-fluorodeoxyglucose (FDG)) and the combined examination with computed tomography (PET/CT)
were considerably improved with last generation PET/CT machines. New generation PET/CT
machines provide significantly improved image quality and image resolution image, and
probably higher sensitivity to detect smaller lesions. However, in the face of an expected
increase of detected metabolically active cervical lymph nodes by high-resolution (HR)
PET/CT, a diagnostic problem in terms of a potentially increased number of false-positive
lymph nodes arises, e. g. due to an inflammatory lymphadenopathy.
Until now there are no evidence-based criteria to classify small metabolically active lymph
nodes detected by HR PET/CT. Hence, a correlation of PET/CT findings and histopathology of
cervical lymph metastases and inflammatory lymph nodes in patients with HNSCC is required to
develop diagnostic criteria for HR PET/CT and to exploit the diagnostic potential of HR
PET/CT.
Modern concepts of radiotherapy planning for neck lymph node metastases increasingly take
into consideration the metabolic and morphological information of PET/CT for target volume
definition. Detailed information on the diagnostic performance of HR PET / CT are of
importance for the dose prescription of intensity-modulated radiotherapy (IMRT). In
radiotherapy side effects depend significantly on the dose and the irradiation volume. Modern
radiation techniques, especially IMRT, allow for highly-conformal radiation therapy with
steep dose gradients to protect organs such as the salivary glands, and to reduce side
effects of radiotherapy. On the other hand modern radiotherapy concepts carry the risk to
fail due to non-inclusion of subclinical lymph node metastases in the target volume. HR
PET/CT may allow to minimize out-of-field recurrences caused by incorrect target volume
contouring or dose prescription. Evidence-based data on the diagnostic accuracy of HR PET/CT
with special regard to small lymph node metastases are needed to clarify the potential role
of HR PET/CT for radiation treatment planning.
Objective:
- To determine the sensitivity, specificity, accuracy, PPV and NPV of lymph node staging
with HR PET/CT in patients with HNSCC
- To determine the sensitivity, specificity, accuracy, PPV and NPV of HR PET/CT for lymph
node metastases of different size in patients with HNSCC
- To determine the detection rate of distant metastases by PET/CT in patients with HNSCC
- To develop diagnostic criteria for the multi-modal lymph node staging with HR PET/CT in
patients with HNSCC
- To evaluate the potential impact of HR PET/CT on radiation treatment planning
Methods:
Patients with HNSCC are managed according to clinical recommendations of the
interdisciplinary tumor board. Elective patients receive selective, modified radical or
radical neck dissection of the relevant lymph node region according to clinical routine
standards at the Inselspital Bern. The neck dissection must be carried out within a maximum
of 6 weeks after the PET / CT examination.
As part of the neck dissection the lymph nodes will be sent to the Institute of Pathology
separated by level and side by topographic markers (cranial / caudal, medial / lateral). The
histological examination of the removed lymph nodes serves as reference standard for the
analysis of PET/CT image data, and calculation of the diagnostic accuracy of HR PET/CT.
Theoretical radiation treatment plans are generated based on conventional imaging, whole-body
PET/CT and HR PET/CT protocols to determine the impact of PET/CT.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05331131 -
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial
|
Phase 2 | |
Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
Completed |
NCT03574870 -
Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04804852 -
Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer
|
||
Active, not recruiting |
NCT04617678 -
A Comprehensive Approach to Head and Neck Cancer Prehabilitation
|
N/A | |
Completed |
NCT03419741 -
Brain Stimulation For Cancer Smokers
|
N/A | |
Recruiting |
NCT02528955 -
De-Intensification Radiotherapy Postoperative Head Neck
|
Phase 2 | |
Completed |
NCT00318890 -
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
|
Phase 1/Phase 2 | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Recruiting |
NCT05316974 -
Lymphoedema Among Persons With Head- and Neck Cancer
|
||
Not yet recruiting |
NCT03954691 -
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies
|
||
Active, not recruiting |
NCT03760471 -
Palliative and Oncology Care Intervention: Symptom COACH
|
N/A | |
Completed |
NCT04554667 -
Heavy Lifting Strength Training in Head and Neck Cancer Survivors
|
Phase 1 | |
Completed |
NCT02869399 -
Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention
|
N/A | |
Completed |
NCT02366611 -
Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer
|
N/A | |
Completed |
NCT02075112 -
Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
|
Phase 1 | |
Completed |
NCT00798655 -
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT02900911 -
Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy
|
N/A | |
Completed |
NCT01317589 -
Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
|
Phase 4 | |
Completed |
NCT03841175 -
Forecasts Impact of the Pre-therapeutic TEP-TDM in the 18-FDG Restaging of Upper Aero-digestive Tract Cancers
|